ArticleScientific reports2026
Population-based comparison of post-acute sequelae of COVID-19 and health-related quality of life across pandemic periods: Omicron era versus early pandemic.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-COVID-19 syndrome (PCS) may vary across pandemic phases. We compared the prevalence of post-acute COVID-19 symptom clusters following SARS-CoV-2 infection in the early pandemic and during the Omicron era using a population-based approach. The EPILOC study enrolled individuals aged 18-65 years who tested PCR-positive for SARS-CoV-2 during the early pandemic, between October 2020 and April 2021, in defined geographic regions within Baden-Württemberg. EPILOC-Omicron used an identical design for individuals infected between June and July 2022. Participants completed a standardised questionnaire assessing sociodemographics, lifestyle, symptoms, and health-related quality of life (SF-12). PCS was defined as ≤ 80% recovery of general health or work capacity plus at least one new moderate-to-strong symptom, both compared to before index infection. Generalised linear models adjusted for age, sex, and education were used to estimate relative risks (RRs). We analysed data from 11,710 EPILOC (24% response) and 12,560 EPILOC-Omicron participants (17% response). Participants were similar in age and sex distribution. Vaccination before infection differed markedly (< 3 vs. > 92%). PCS prevalence was 29.6% in EPILOC and 14.5% in EPILOC-Omicron. Predictors of PCS were similar for both. Symptom clusters were consistently less frequent after infection during the Omicron era (e.g., fatigue RR = 0.54; neurocognitive impairment RR = 0.53; chest symptoms RR = 0.47; smell/taste disorder RR = 0.17). Health-related quality of life was similar in PCS cases of both cohorts (mean SF-12
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.